Our Solution
R&D Pipeline
Koru Biotech is advancing its efforts to provide innovative solutions for the rapid detection, treatment and prevention of infections in both animals and humans. Our current research and development portfolio is focused on the delivery of solutions specifically to address key global health issues with Coliform Mastitis in dairy cows and Enteritis in calves.
Rapid Diagnostic Kit for Coliform Mastitis
This point-of-care lateral flow test (similar to a COVID-19 rapid antigen test) detects a specific LPS biomarker in under 15 minutes. By providing rapid results, veterinarians and dairy farmers can make informed treatment decisions immediately, without waiting 24 hours for culture-based test results. This faster diagnosis ensures targeted treatments, reduces unnecessary antibiotic use, and improves recovery rates.
Non-Antibiotic Treatment for Coliform Mastitis
Our innovative therapeutic treatment targets LPS toxicity directly, disrupting the severe inflammatory response that typically occurs during infection. This approach helps cows recover more quickly, reducing milk loss and preventing the overuse of antibiotics, which can exacerbate inflammation and prolong recovery.
Prophylactic Oral Vaccine for Newborn Calves
Our novel vaccine boosts immunity in newborn calves, offering protection against enteritis. The vaccine induces the production of IgA antibodies, which are detectable in saliva and feces, offering robust protection at mucosal surfaces. This breakthrough approach has potential applications for a wide range of mucosal diseases.
Commercial
StaphGold ELISA Kit – Lab Test to Detect Antibodies to Staphylococcus aureus Mastitis
The Staphgold test has sensitivity and specificity of >90% in detecting subclinical Staphylococcus aureus, a major cause of milk loss and degradation of quality. The test utilises herd test samples providing a cost effective tool for whole herd screening ahead of dry off and at the start of the following lactation. This allows producers and their vets to confidently selective dry cow therapy and to implement more effective herd management strategies through lactation. Staphgold is in the early stages of commercialisation in Australia, New Zealand and the USA.